Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
– NCCN Guidelines Include QINLOCK as a Preferred Regimen for Second-Line GIST Patients Intolerant to Sunitinib –
– Breakthrough Therapy Designation is Based on Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 –
– Company Plans to Initiate the INSIGHT Pivotal Phase 3 Study of QINLOCK Versus Sunitinib in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 in the Second Half of 2023–
WALTHAM, Mass.–(BUSINESS WIRE)–Mar. 14, 2023– Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that QINLOCK® (ripretinib) has been included in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology as a preferred regimen for second-line gastrointestinal stromal tumor (GIST) patients intolerant to sunitinib.
The Company also announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for QINLOCK for the treatment of adult patients with unresectable or metastatic GIST who received prior treatment with imatinib, and who harbor a KIT exon 11 mutation and co-occurring KIT exon 17 and/or 18 mutations (KIT exon 11+17/18 mutations). QINLOCK is Deciphera’s switch-control inhibitor currently approved in 12 territories around the world, including major markets of the United States, Europe, and China for the treatment of fourth-line GIST.
“The Breakthrough Therapy Designation reflects the substantial clinical benefit of QINLOCK in second-line GIST patients harboring mutations in KIT exon 11 and 17/18 that we observed in the ctDNA analysis from the INTRIGUE Phase 3 study. If approved, we believe QINLOCK has the potential to become the standard-of-care for this group of second-line GIST patients around the world. GIST key opinion leaders and physicians have long been proponents of clinical drug development targeted at specific molecular subtypes of GIST, and we are pleased with the FDA’s recognition that the ctDNA data indicates QINLOCK may demonstrate substantial improvement over the current standard-of-care in this population,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “Further, the inclusion of QINLOCK in the latest NCCN clinical practice guidelines underscores both the need for additional treatment options for GIST patients in the post-imatinib setting and the significance of the results from the INTRIGUE study, which demonstrated that QINLOCK is an active and well-tolerated agent.”
The update to the NCCN GIST Guidelines is based on the primary analysis of the INTRIGUE Phase 3 study as published in the Journal of Clinical Oncology (Bauer S, Jones RL, Blay JY, et al. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): A randomized, open-label, phase III trial. J Clin Oncol 2022; 40: 3918-3928). Key study results include:
In the intention-to-treat (ITT) population (n=453), QINLOCK demonstrated a median PFS (mPFS) of 8.0 months compared to 8.3 months for the sunitinib arm (Hazard Ratio [HR] 1.05, nominal p value=0.72).
Ripretinib was generally well tolerated. Fewer patients in the QINLOCK arm experienced Grade 3/4 treatment-emergent adverse events compared to sunitinib (41.3% vs 65.6%).
Patients receiving sunitinib were three times more likely to develop Grade 3 hypertension compared to patients receiving QINLOCK (26.7% vs. 8.5%) and patients receiving sunitinib were seven times more likely to develop Grade 3 palmar-plantar erythrodysesthesia compared to patients receiving QINLOCK (10.0% vs. 1.3%).
Patient reported outcome measures also showed a more favorable tolerability profile for patients receiving QINLOCK compared to patients receiving sunitinib. Patients receiving QINLOCK experienced less deterioration in their ability to engage in either work or leisure activities during treatment, and fewer patients receiving QINLOCK experienced moderate to extremely large impact on their lives due to skin toxicity across treatment cycles compared to patients receiving sunitinib.
The updated NCCN Guidelines are available online at www.nccn.org.
The FDA’s BTD is intended to expedite the development and review of a medicine aiming to treat a serious or life-threatening disease with preliminary clinical evidence that indicates the drug may demonstrate substantial improvement over existing therapies. This is the second BTD granted to QINLOCK. The BTD is supported by an exploratory analysis from the INTRIGUE Phase 3 study in GIST patients previously treated with imatinib to evaluate anti-tumor efficacy of QINLOCK according to baseline KIT primary and secondary mutation status using circulating tumor DNA (ctDNA). Patients with mutations in KIT exon 11 and exon 17/18 only (n=52) derived substantially improved clinical benefit with QINLOCK versus sunitinib. Key results of the ctDNA analysis in the KIT exon 11 and 17/18 subgroup include:
QINLOCK demonstrated an mPFS of 14.2 months compared to 1.5 months for the sunitinib arm (HR 0.22, nominal p value <0.0001).
QINLOCK demonstrated a confirmed objective response rate (ORR) of 44.4% (n=12 of 27) compared to 0% for sunitinib (nominal p value 0.0001).
OS for the QINLOCK arm has not reached a median, while patients randomized to the sunitinib arm had a median OS (mOS) of 17.5 months (HR 0.34, nominal p value 0.0061).
The subgroup safety profiles were consistent with the primary analysis.